Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 8:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 233 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ablative Radiotherapy Clear all
Recruiting Not applicable Interventional

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

NCT04959474
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
Interventions
Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention, Questionnaire Administration, Quality-of-Life Assessment, Mammography, Biospecimen Collection
Other · Radiation · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Completed Early Phase 1 Interventional

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

NCT03158883
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer (NSCLC)
Interventions
Avelumab, Stereotactic ablative radiotherapy (SAR)
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 12, 2026, 8:36 PM EDT
Active, not recruiting Phase 3 Interventional

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

NCT05863351
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Stereotactic Ablative Radiotherapy, Systemic Therapy
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2037
U.S. locations
108
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Recruiting Not applicable Interventional

SBRT Boost for Unfavorable Prostate Cancer'

NCT02016248
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic body radiotherapy (SBRT) Boost
Radiation
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
3
States / cities
Fountain Valley, California • Laguna Hills, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Recruiting Phase 2 Interventional

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

NCT07603856
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Interventions
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Not listed Phase 1 Interventional

A Phase I Study Evaluating the Safety of Stereotactic Central Ablative Radiation Therapy (SCART) for Bulky Metastatic or Recurrent Cancer

NCT04881981
View directory record Official record
Conditions
Malignant Neoplasms
Interventions
SCART radiation therapy
Radiation
Lead sponsor
Baptist Health, Louisville
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Corbin, Kentucky • Morehead, Kentucky
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 12, 2026, 8:36 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

NCT02141919
View directory record Official record
Conditions
Renal Cancers
Interventions
Stereotactic Ablative Radiation Therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 12, 2026, 8:36 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NCT05624996
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
476
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Withdrawn Not applicable Interventional

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

NCT04399824
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 12, 2026, 8:36 PM EDT
Withdrawn Not applicable Interventional

Acne Scarring in Skin of Color: Laser vs Microneedling

NCT03395678
View directory record Official record
Conditions
Acne Vulgaris, Scar
Interventions
Microneedling, Fractional non-ablative 1,540nm laser
Device
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 12, 2026, 8:36 PM EDT
Recruiting Not applicable Interventional

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

NCT06103682
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
Interventions
Ablative local therapy
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

NCT02311361
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Interventions
Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT)
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 12, 2026, 8:36 PM EDT
Not listed Phase 2 Interventional

Definitive Therapy for Oligometastatic Solid Malignancies

NCT01898962
View directory record Official record
Conditions
Stage IV or Recurrent Carcinoma or Sarcoma
Interventions
Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose, Subtotal surgical removal plus ablative radiation dose, Radioembolization
Procedure · Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • Boulder, Colorado • Littleton, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 12, 2026, 8:36 PM EDT
Recruiting Not applicable Interventional

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

NCT05679674
View directory record Official record
Conditions
Pancreas Cancer, Locally Advanced, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Stereotactic Ablative Body Radiation (SABR), Tumor Treating Fields (TTF)
Radiation · Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Active, not recruiting Phase 1 Interventional

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

NCT02353819
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Ablative Radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Completed Phase 2 Interventional Results available

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

NCT01818986
View directory record Official record
Conditions
Metastatic Castrate-resistant Prostate Cancer, mCRPC
Interventions
Sipuleucel-T, Stereotactic Ablative Body Radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 12, 2026, 8:36 PM EDT
Not yet recruiting Phase 2 Interventional

Defining the Ablative Dose for Y-90 TARE

NCT07586046
View directory record Official record
Conditions
HCC - Hepatocellular Carcinoma
Interventions
Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Recruiting Not applicable Interventional

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

NCT06325046
View directory record Official record
Conditions
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Computed Tomography, Cone-Beam Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Ablative Radiotherapy, Survey Administration
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
Albert Lea, Minnesota • Mankato, Minnesota • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 12, 2026, 8:36 PM EDT
Terminated Not applicable Interventional Results available

Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer

NCT01797471
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC
Interventions
Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
Radiation
Lead sponsor
University of Miami
Other
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 12, 2026, 8:36 PM EDT
Terminated Phase 1Phase 2 Interventional

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

NCT03618134
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab
Biological · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 12, 2026, 8:36 PM EDT
Not listed No phase listed Observational

Breath Test for Biomarkers in Humans Receiving Total Body Irradiation

NCT02152722
View directory record Official record
Conditions
Radiation Injury
Interventions
Not listed
Lead sponsor
Menssana Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 12, 2026, 8:36 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC

NCT05691829
View directory record Official record
Conditions
NSCLC Stage IV
Interventions
Pembrolizumab, Radiation, Chemotherapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 12, 2026, 8:36 PM EDT
Terminated Phase 1 Interventional

Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer

NCT02252796
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Hypofractionated Stereotactic Boost, Carboplatin, Paclitaxel, Image-guided IMRT
Radiation · Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 12, 2026, 8:36 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
391
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 12, 2026, 8:36 PM EDT